300 related articles for article (PubMed ID: 31201024)
1. Multi-Gene Panel Testing of 23,179 Individuals for Hereditary Cancer Risk Identifies Pathogenic Variant Carriers Missed by Current Genetic Testing Guidelines.
Neben CL; Zimmer AD; Stedden W; van den Akker J; O'Connor R; Chan RC; Chen E; Tan Z; Leon A; Ji J; Topper S; Zhou AY
J Mol Diagn; 2019 Jul; 21(4):646-657. PubMed ID: 31201024
[TBL] [Abstract][Full Text] [Related]
2. Analysis of hereditary cancer syndromes by using a panel of genes: novel and multiple pathogenic mutations.
Tsaousis GN; Papadopoulou E; Apessos A; Agiannitopoulos K; Pepe G; Kampouri S; Diamantopoulos N; Floros T; Iosifidou R; Katopodi O; Koumarianou A; Markopoulos C; Papazisis K; Venizelos V; Xanthakis I; Xepapadakis G; Banu E; Eniu DT; Negru S; Stanculeanu DL; Ungureanu A; Ozmen V; Tansan S; Tekinel M; Yalcin S; Nasioulas G
BMC Cancer; 2019 Jun; 19(1):535. PubMed ID: 31159747
[TBL] [Abstract][Full Text] [Related]
3. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
[TBL] [Abstract][Full Text] [Related]
4. Identification of a Variety of Mutations in Cancer Predisposition Genes in Patients With Suspected Lynch Syndrome.
Yurgelun MB; Allen B; Kaldate RR; Bowles KR; Judkins T; Kaushik P; Roa BB; Wenstrup RJ; Hartman AR; Syngal S
Gastroenterology; 2015 Sep; 149(3):604-13.e20. PubMed ID: 25980754
[TBL] [Abstract][Full Text] [Related]
5. Opportunistic testing of BRCA1, BRCA2 and mismatch repair genes improves the yield of phenotype driven hereditary cancer gene panels.
Feliubadaló L; López-Fernández A; Pineda M; Díez O; Del Valle J; Gutiérrez-Enríquez S; Teulé A; González S; Stjepanovic N; Salinas M; Capellá G; Brunet J; Lázaro C; Balmaña J;
Int J Cancer; 2019 Nov; 145(10):2682-2691. PubMed ID: 30927264
[TBL] [Abstract][Full Text] [Related]
6. Hereditary cancer-associated mutations in women diagnosed with two primary cancers: an opportunity to identify hereditary cancer syndromes after the first cancer diagnosis.
Saam J; Moyes K; Landon M; Williams K; Kaldate RR; Arnell C; Wenstrup R
Oncology; 2015; 88(4):226-33. PubMed ID: 25503195
[TBL] [Abstract][Full Text] [Related]
7. Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients.
Crawford B; Adams SB; Sittler T; van den Akker J; Chan S; Leitner O; Ryan L; Gil E; van 't Veer L
Breast Cancer Res Treat; 2017 Jun; 163(2):383-390. PubMed ID: 28281021
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of nonfounder BRCA1/2 mutations in Ashkenazi Jewish patients presenting for genetic testing at a hereditary breast and ovarian cancer center.
Frey MK; Kopparam RV; Ni Zhou Z; Fields JC; Buskwofie A; Carlson AD; Caputo T; Holcomb K; Chapman-Davis E
Cancer; 2019 Mar; 125(5):690-697. PubMed ID: 30480775
[TBL] [Abstract][Full Text] [Related]
9. The spectrum of genetic variants in hereditary pancreatic cancer includes Fanconi anemia genes.
Slavin TP; Neuhausen SL; Nehoray B; Niell-Swiller M; Solomon I; Rybak C; Blazer K; Adamson A; Yang K; Sand S; Guerrero-Llamas N; Castillo D; Herzog J; Wu X; Tao S; Raja S; Chung V; Singh G; Nadesan S; Brown S; Cruz-Correa M; Petersen GM; Weitzel J;
Fam Cancer; 2018 Apr; 17(2):235-245. PubMed ID: 28687971
[TBL] [Abstract][Full Text] [Related]
10. Genetic Predisposition to Breast Cancer Due to Mutations Other Than BRCA1 and BRCA2 Founder Alleles Among Ashkenazi Jewish Women.
Walsh T; Mandell JB; Norquist BM; Casadei S; Gulsuner S; Lee MK; King MC
JAMA Oncol; 2017 Dec; 3(12):1647-1653. PubMed ID: 28727877
[TBL] [Abstract][Full Text] [Related]
11. A substantial proportion of apparently heterozygous TP53 pathogenic variants detected with a next-generation sequencing hereditary pan-cancer panel are acquired somatically.
Coffee B; Cox HC; Bernhisel R; Manley S; Bowles K; Roa BB; Mancini-DiNardo D
Hum Mutat; 2020 Jan; 41(1):203-211. PubMed ID: 31490007
[TBL] [Abstract][Full Text] [Related]
12. Underdiagnosis of Hereditary Breast Cancer: Are Genetic Testing Guidelines a Tool or an Obstacle?
Beitsch PD; Whitworth PW; Hughes K; Patel R; Rosen B; Compagnoni G; Baron P; Simmons R; Smith LA; Grady I; Kinney M; Coomer C; Barbosa K; Holmes DR; Brown E; Gold L; Clark P; Riley L; Lyons S; Ruiz A; Kahn S; MacDonald H; Curcio L; Hardwick MK; Yang S; Esplin ED; Nussbaum RL
J Clin Oncol; 2019 Feb; 37(6):453-460. PubMed ID: 30526229
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic yield of multigene panel testing in an Israeli cohort: enrichment of low-penetrance variants.
Bernstein-Molho R; Friedman E; Kedar I; Laitman Y; Allweis TM; Gal-Yam EN; Feldman HB; Grinshpun A; Halpern N; Hartmajer S; Kadouri L; Katz LH; Kaufman B; Laish I; Levanon K; Philipsborn SL; Ludman M; Moran G; Peretz T; Reinstein E; Levi GR; Safra T; Shkedi S; Vinkler C; Levy Z; Goldberg Y
Breast Cancer Res Treat; 2020 Jun; 181(2):445-453. PubMed ID: 32303989
[TBL] [Abstract][Full Text] [Related]
14. Germline genetic variants in men with prostate cancer and one or more additional cancers.
Pilié PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA
Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667
[TBL] [Abstract][Full Text] [Related]
15. The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?
Eliade M; Skrzypski J; Baurand A; Jacquot C; Bertolone G; Loustalot C; Coutant C; Guy F; Fumoleau P; Duffourd Y; Arnould L; Delignette A; Padéano MM; Lepage C; Raichon-Patru G; Boudrant A; Bône-Lépinoy MC; Villing AL; Charpin A; Peignaux K; Chevrier S; Vegran F; Ghiringhelli F; Boidot R; Sevenet N; Lizard S; Faivre L
Oncotarget; 2017 Jan; 8(2):1957-1971. PubMed ID: 27779110
[TBL] [Abstract][Full Text] [Related]
16. Hereditary predisposition to ovarian cancer, looking beyond BRCA1/BRCA2.
Minion LE; Dolinsky JS; Chase DM; Dunlop CL; Chao EC; Monk BJ
Gynecol Oncol; 2015 Apr; 137(1):86-92. PubMed ID: 25622547
[TBL] [Abstract][Full Text] [Related]
17. Utility of Expedited Hereditary Cancer Testing in the Surgical Management of Patients with a New Breast Cancer Diagnosis.
Theobald KA; Susswein LR; Marshall ML; Roberts ME; Mester JL; Speyer D; Williams RNW; Knapke SC; Solomon SR; Murphy PD; Klein RT; Hruska KS; Solomon BD
Ann Surg Oncol; 2018 Nov; 25(12):3556-3562. PubMed ID: 30167906
[TBL] [Abstract][Full Text] [Related]
18. Next-generation universal hereditary cancer screening: implementation of an automated hereditary cancer screening program for patients with advanced cancer undergoing tumor sequencing in a large HMO.
Hoffman TL; Kershberg H; Goff J; Holmquist KJ; Haque R; Alvarado M
Fam Cancer; 2023 Apr; 22(2):225-235. PubMed ID: 36261688
[TBL] [Abstract][Full Text] [Related]
19. Multigene panels in Ashkenazi Jewish patients yield high rates of actionable mutations in multiple non-BRCA cancer-associated genes.
Frey MK; Sandler G; Sobolev R; Kim SH; Chambers R; Bassett RY; Martineau J; Sapra KJ; Boyd L; Curtin JP; Pothuri B; Blank SV
Gynecol Oncol; 2017 Jul; 146(1):123-128. PubMed ID: 28495237
[TBL] [Abstract][Full Text] [Related]
20. Mutation prevalence tables for hereditary cancer derived from multigene panel testing.
Hart SN; Polley EC; Yussuf A; Yadav S; Goldgar DE; Hu C; LaDuca H; Smith LP; Fujimoto J; Li S; Couch FJ; Dolinsky JS
Hum Mutat; 2020 Aug; 41(8):e1-e6. PubMed ID: 32442341
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
